Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413322 · ClinicalTrials.gov registry record · Phase 1
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00413322 is a Phase 1 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT00413322, a Phase 1 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).
Interventions
- DRUG 5-Fluorouracil (5-FU)
- DRUG belinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413322
The ClinicalTrials.gov registry entry for NCT00413322 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5-Fluorouracil (5-FU) is the first listed.
NCT00413322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413322 about?
NCT00413322 is a clinical study titled "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors". This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).
What is the current status of trial NCT00413322?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2005-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00413322?
The interventions under investigation include: 5-Fluorouracil (5-FU) (DRUG), belinostat (DRUG).
Who is sponsoring clinical trial NCT00413322?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.